Sage Journals: Discover world-class research

Retricted access

Other

First published 2009-11

Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy

Patricia K Coyle, John F Foley, Edward J Fox [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2021-3

Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri ® Observational Program (TOP)

Helmut Butzkueven, Maria Trojano, Ludwig Kappos [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2013-8

Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes

Angela Vidal-Jordana, Jaume Sastre-Garriga, Francisco Pérez-Miralles [...]

Multiple Sclerosis Journal

Retricted access

Other

First published 2008-06

Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy

JR Berger

Multiple Sclerosis Journal

Free access

Research article

First published 2012-3

From injection therapies to natalizumab: views on the treatment of multiple sclerosis

Roberto Bomprezzi, Darin T. Okuda, Yazan J. Alderazi [...]

Therapeutic Advances in Neurological Disorders

Retricted access

Research article

First published 2012-11

Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod

Sebastian Jander, Bernd Turowski, Bernd C Kieseier [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2012-1

Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy

MH Barnett, JW Prineas, ME Buckland [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2019

Therapy with cladribine is efficient and safe in patients previously treated with natalizumab

Nora Möhn, Thomas Skripuletz, Kurt-Wolfram Sühs [...]

Therapeutic Advances in Neurological Disorders

Open access

Research article

First published 2020-1

Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population

Devon S Conway, Carrie M Hersh, Haleigh C Harris [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Retricted access

Research article

First published 2013-8

Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy

A Harrer, H Tumani, S Niendorf [...]

Multiple Sclerosis Journal

Search results